Prediction of Pathologic Complete Response in Breast Cancer Patients Comparing Magnetic Resonance Imaging with Ultrasound in Neoadjuvant Setting

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2021 May 27

PMID 34043094

Citations 8

Authors

Frederik Knude Palshof

Charlotte Lanng

Niels Kroman

Cemil Benian

Ilse Vejborg

Anne Bak

Maj-Lis Talman

Eva Balslev

Tove Filtenborg Tvedskov

Affiliations

Soon will be listed here.

Abstract

Background: Some subgroups of breast cancer patients receiving neoadjuvant chemotherapy (NACT) show high rates of pathologic complete response (pCR) in the breast, proposing the possibility of omitting surgery. Prediction of pCR is dependent on accurate imaging methods. This study investigated whether magnetic resonance imaging (MRI) is better than ultrasound (US) in predicting pCR in breast cancer patients receiving NACT.

Methods: This institutional, retrospective study enrolled breast cancer patients receiving NACT who were examined by either MRI or combined US and mammography before surgery from 2016 to 2019. Imaging findings were compared with pathologic response evaluation of the tumor. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy for prediction of pCR were calculated and compared between MRI and US.

Results: Among 307 patients, 151 were examined by MRI and 156 by US. In the MRI group, 37 patients (24.5 %) had a pCR compared with 51 patients (32.7 %) in the US group. Radiologic complete response (rCR) was found in 35 patients (23.2 %) in the MRI group and 26 patients (16.7 %) in the US group. In the MRI and US groups, estimates were calculated respectively for sensitivity (87.7 % vs 91.4 %), specificity (56.8 % vs 33.3 %), PPV (86.2 % vs 73.8 %), NPV (60.0 % vs 65.4 %), and accuracy (80.1 % vs 72.4 %).

Conclusions: In predicting pCR, MRI was more specific than US, but not sufficiently specific enough to be a valid predictor of pCR for omission of surgery. As an imaging method, MRI should be preferred when future studies investigating prediction of pCR in NACT patients are planned.

Citing Articles

Surgery paradigm for locally advanced breast cancer following neoadjuvant systemic therapy.

Sun Z, Liu K, Guo Y, Jiang N, Ye M Front Surg. 2024; 11:1410127.

PMID: 39308852 PMC: 11412956. DOI: 10.3389/fsurg.2024.1410127.

Correlation and predictive value of pathological complete response and ultrasound characteristic parameters in neoadjuvant chemotherapy for breast.

Zheng L, Yang L, Liu J, Jiang Z, Li X, Pu P World J Clin Cases. 2024; 12(23):5320-5328.

PMID: 39156092 PMC: 11238688. DOI: 10.12998/wjcc.v12.i23.5320.

Predictive value of ultrasound doppler parameters in neoadjuvant chemotherapy response of breast cancer: Prospective comparison with magnetic resonance and mammography.

Conz L, Jales R, Doria M, Melloni I, Cres Lyrio C, Menossi C PLoS One. 2024; 19(6):e0302527.

PMID: 38833499 PMC: 11149875. DOI: 10.1371/journal.pone.0302527.

Application of triple evaluation method in predicting the efficacy of neoadjuvant therapy for breast cancer.

Han X, Li H, Dong S, Zhou S, Wang C, Guo L World J Surg Oncol. 2023; 21(1):116.

PMID: 36978164 PMC: 10052864. DOI: 10.1186/s12957-023-02998-8.

Preoperative Partial Breast Irradiation in Patients with Low-Risk Breast Cancer: A Systematic Review of Literature.

Civil Y, Jonker L, Groot Koerkamp M, Duvivier K, de Vries R, Oei A Ann Surg Oncol. 2023; 30(6):3263-3279.

PMID: 36869253 PMC: 10175515. DOI: 10.1245/s10434-023-13233-9.

References

Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher E . Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16(8):2672-85. DOI: 10.1200/JCO.1998.16.8.2672. View

Rastogi P, Anderson S, Bear H, Geyer C, Kahlenberg M, Robidoux A . Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008; 26(5):778-85. DOI: 10.1200/JCO.2007.15.0235. View

Chen M, Zhan W, Han B, Fei X, Jin X, Chai W . Accuracy of physical examination, ultrasonography, and magnetic resonance imaging in predicting response to neo-adjuvant chemotherapy for breast cancer. Chin Med J (Engl). 2012; 125(11):1862-6. View

Hayashi N, Tsunoda H, Namura M, Ochi T, Suzuki K, Yamauchi H . Magnetic Resonance Imaging Combined With Second-look Ultrasonography in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Primary Breast Cancer Patients. Clin Breast Cancer. 2018; 19(1):71-77. DOI: 10.1016/j.clbc.2018.08.004. View

Bouzon A, Iglesias A, Acea B, Mosquera C, Santiago P, Mosquera J . Evaluation of MRI accuracy after primary systemic therapy in breast cancer patients considering tumor biology: optimizing the surgical planning. Radiol Oncol. 2019; 53(2):171-177. PMC: 6572491. DOI: 10.2478/raon-2019-0023. View

Fukuda T, Horii R, Gomi N, Miyagi Y, Takahashi S, Ito Y . Accuracy of magnetic resonance imaging for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy: association with breast cancer subtype. Springerplus. 2016; 5:152. PMC: 4766139. DOI: 10.1186/s40064-016-1800-x. View

Namura M, Tsunoda H, Yagata H, Hayashi N, Yoshida A, Morishita E . Discrepancies Between Pathological Tumor Responses and Estimations of Complete Response by Magnetic Resonance Imaging After Neoadjuvant Chemotherapy Differ by Breast Cancer Subtype. Clin Breast Cancer. 2017; 18(2):128-134. DOI: 10.1016/j.clbc.2017.07.001. View

Houssami N, Macaskill P, von Minckwitz G, Marinovich M, Mamounas E . Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer. 2012; 48(18):3342-54. DOI: 10.1016/j.ejca.2012.05.023. View

van der Noordaa M, van Duijnhoven F, Loo C, van Werkhoven E, Van de Vijver K, Wiersma T . Identifying pathologic complete response of the breast after neoadjuvant systemic therapy with ultrasound guided biopsy to eventually omit surgery: Study design and feasibility of the MICRA trial (Minimally Invasive Complete Response Assessment). Breast. 2018; 40:76-81. DOI: 10.1016/j.breast.2018.04.015. View

10.

Kuerer H, Rauch G, Krishnamurthy S, Adrada B, Caudle A, DeSnyder S . A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. 2017; 267(5):946-951. PMC: 6051523. DOI: 10.1097/SLA.0000000000002313. View

11.

Schaefgen B, Mati M, Sinn H, Golatta M, Stieber A, Rauch G . Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response?. Ann Surg Oncol. 2015; 23(3):789-95. DOI: 10.1245/s10434-015-4918-0. View

12.

Shin H, Kim H, Ahn J, Kim S, Jung K, Gong G . Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. Br J Radiol. 2010; 84(1003):612-20. PMC: 3473500. DOI: 10.1259/bjr/74430952. View

13.

Marinovich M, Macaskill P, Irwig L, Sardanelli F, von Minckwitz G, Mamounas E . Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy. Br J Cancer. 2013; 109(6):1528-36. PMC: 3776985. DOI: 10.1038/bjc.2013.473. View

14.

Vriens B, de Vries B, Lobbes M, van Gastel S, van den Berkmortel F, Smilde T . Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer. Eur J Cancer. 2015; 52:67-76. DOI: 10.1016/j.ejca.2015.10.010. View

15.

Park J, Chae E, Cha J, Shin H, Choi W, Choi Y . Comparison of mammography, digital breast tomosynthesis, automated breast ultrasound, magnetic resonance imaging in evaluation of residual tumor after neoadjuvant chemotherapy. Eur J Radiol. 2018; 108:261-268. DOI: 10.1016/j.ejrad.2018.09.032. View

16.

Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G . Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol. 2004; 14(8):1371-9. DOI: 10.1007/s00330-004-2246-z. View

17.

Muller H, Posch F, Suppan C, Bargfrieder U, Gumpoldsberger M, Hammer R . Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy. Ann Surg Oncol. 2019; 26(13):4274-4283. PMC: 6864028. DOI: 10.1245/s10434-019-07741-w. View

18.

Ponde N, Bradbury I, Lambertini M, Ewer M, Campbell C, Ameels H . Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06). Breast Cancer Res Treat. 2017; 168(3):631-638. PMC: 5843537. DOI: 10.1007/s10549-017-4628-3. View

19.

Hennessy B, Hortobagyi G, Rouzier R, Kuerer H, Sneige N, Buzdar A . Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005; 23(36):9304-11. DOI: 10.1200/JCO.2005.02.5023. View

20.

Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S . Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a.... Lancet. 2010; 375(9712):377-84. DOI: 10.1016/S0140-6736(09)61964-4. View